Is there a folate-related gene-environment interaction in the etiology of childhood acute lymphoblastic leukemia?

Elizabeth Milne1, Nicholas H de Klerk, Frank van Bockxmeer

  • 1Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, WA, Australia. lizm@ichr.uwa.edu.au

Insights

Maternal folate supplementation and child

Area of Science:

  • Pediatric Oncology
  • Nutritional Epidemiology
  • Genetic Epidemiology

Background:

  • Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancer.
  • Maternal folate intake and child's methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms are potential factors in ALL etiology.
  • Previous research suggests a protective effect of maternal folate supplementation and certain MTHFR genotypes against childhood ALL.

Purpose of the Study:

  • To investigate the interaction between maternal folate supplementation during pregnancy and the child's MTHFR genotype (C677T and A1298C) in relation to childhood ALL risk.
  • To analyze data from a previous study on childhood ALL cases.

Main Methods:

  • Case-only analysis was employed using bone marrow DNA from 82 childhood ALL cases.
  • Genotyping for MTHFR C677T and A1298C polymorphisms was performed.
  • Case-only odds ratios (COR) were calculated to assess the association between MTHFR genotype, folate supplementation, and ALL.

Main Results:

  • No significant departure from a multiplicative model was observed, indicating no statistically significant interaction between maternal folate supplementation and the child's MTHFR genotype (C677T or A1298C) in relation to ALL risk.
  • Adjustments for sex, age, or the other MTHFR locus genotype did not alter the findings.

Conclusions:

  • This study did not find evidence of an interaction between maternal folate supplementation and child's MTHFR genotype in childhood ALL.
  • Contradictory findings in gene-environment interaction studies may stem from differing definitions of folate exposure.
  • Further research is warranted to elucidate the complex interplay of folate intake and genetic factors in ALL and other cancers.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...